Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner
Metrics: PDF 924 views | HTML 1827 views | ?
Frederick Zhehao Zhang1,2,*, Derek Hoi-Hang Ho1,* and Roger Hoi-Fung Wong1
1Department of Biology, Hong Kong Baptist University, Hong Kong SAR, Hong Kong
2Department of Chemistry, University of Hong Kong, Hong Kong SAR, Hong Kong
*These authors contributed equally to this work
Roger Hoi-Fung Wong, email: email@example.com
Keywords: triptolide; HSP90; CDC37; apoptosis; cancer
Received: October 13, 2017 Accepted: February 24, 2018 Published: April 27, 2018
Triptolide (TL) is a potent anti-tumor, anti-inflammatory and immunosuppressive natural compound. Mechanistic studies revealed that TL inhibits tumor growth and triggers programmed cell death. Studies further suggested that TL inhibits heat shock response in cancer cells to induce apoptosis. HSP90β is the major component of heat shock response and is overexpressed in different types of cancers. Given almost all identified HSP90β inhibitors are either N or C-terminal inhibitors, small molecules attacking cysteine(s) in the middle domain might represent a new class of inhibitors. In the current study, we showed that TL inhibits HSP90β in triple manner. Characterization suggests that TL inhibits ATPase activity by preventing ATP binding thus blunts the chaperone activity. TL disrupts HSP90β-CDC37 (co-chaperone) complex through middle domain Cys366 of HSP90β and causes kinase client protein degradation. At the cellular level, the TL-mediated decrease in CDK4 protein levels in HeLa cells causes reduced phosphorylation of Rb resulting in cell cycle arrest at the G1 phase. Furthermore, our results demonstrated that TL triggers programmed cell death in an HSP90β-dependent manner as knockdown of HSP90β further sensitized TL-mediated cell cycle arrest and apoptotic effect. Surprisingly, our data showed that TL is the first drug to be reported to induce site-specific phosphorylation of HSP90β to drive apoptosome formation in the early phase of the treatment.
In summary, our study established that TL is a novel middle domain HSP90β inhibitor with bi-phasic multi-mechanistic inhibition. The unique regulatory mechanism of TL on HSP90β makes it an effective inhibitor.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.